Thrombolysis for acute ischaemic stroke: current status and future perspectives
Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …
Advances in acute ischemic stroke therapy
Y Xiong, AK Wakhloo, M Fisher - Circulation research, 2022 - Am Heart Assoc
The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
Editor's Choice–European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery …
R Naylor, B Rantner, S Ancetti, GJ de Borst… - European Journal of …, 2023 - ejves.com
These guidelines will be updated every four years. Vascular centres are encouraged to audit
implementations made as a result of the guidelines. Audit cycles should be repeated and …
implementations made as a result of the guidelines. Audit cycles should be repeated and …
Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial
U Fischer, J Kaesmacher, D Strbian, O Eker… - The Lancet, 2022 - thelancet.com
Background Whether thrombectomy alone is equally as effective as intravenous alteplase
plus thrombectomy remains controversial. We aimed to determine whether thrombectomy …
plus thrombectomy remains controversial. We aimed to determine whether thrombectomy …
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial
Background There is increasing interest in replacing alteplase with tenecteplase as the
preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to …
preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to …
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint …
CE Kvistad, H Næss, BH Helleberg, T Idicula… - The Lancet …, 2022 - thelancet.com
Background Tenecteplase is a modified tissue plasminogen activator with pharmacological
and practical advantages over alteplase—which is currently the only approved thrombolytic …
and practical advantages over alteplase—which is currently the only approved thrombolytic …
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised …
Background Intravenous thrombolysis with alteplase bolus followed by infusion is a global
standard of care for patients with acute ischaemic stroke. We aimed to determine whether …
standard of care for patients with acute ischaemic stroke. We aimed to determine whether …
Trial of thrombectomy for stroke with a large infarct of unrestricted size
V Costalat, TG Jovin, JF Albucher… - … England Journal of …, 2024 - Mass Medical Soc
Background The use of thrombectomy in patients with acute stroke and a large infarct of
unrestricted size has not been well studied. Methods We assigned, in a 1: 1 ratio, patients …
unrestricted size has not been well studied. Methods We assigned, in a 1: 1 ratio, patients …
Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the ARAMIS randomized clinical trial
HS Chen, Y Cui, ZH Zhou, H Zhang, LX Wang… - Jama, 2023 - jamanetwork.com
Importance Intravenous thrombolysis is increasingly used in patients with minor stroke, but
its benefit in patients with minor nondisabling stroke is unknown. Objective To investigate …
its benefit in patients with minor nondisabling stroke is unknown. Objective To investigate …